If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Definitely on more people’s radar since NED appointments. Half next years revenue already in the bag. News still to come from Monument in which they have a 25 per cent stake having been spun out from Cog. The dots are definitely lining up. It’s almost like the market has valued the acquisitions at zero. This often the case in the market at the moment. Of course this stock is a little illiquid so is very volatile. Let’s hope it gets volatile in an upward move this year
Unfortunately a company that keeps taking from investors to reward the directors. So typical of dross segment of Aim
News flow just keeps flowing. Attendance by CNC at embedded tech forum in USA and news of ‘TNS’ for vehicle architecture’
Unfortunately the markets feel pretty strange right now. Very mixed signals. ‘A rapid rise out of mild recession’ ? Certainly a lot of volatility across the board. I have been in Melbourne for last two months where the economy is extremely buoyant, although property has cooled a little. I met someone from a life science company the other evening and they were very bullish about biotech, agreeing we are on the cusp of some massive advances in medicines . Feel quite a bit more hopeful with N4p but obviously still highly risky. Gl all.
It’s not the private investor that’s going to get this noticed. There are plenty of stocks that just don’t get the investors eye, especially at a time when money is sitting on the fence. What does amaze me is how little notice the medical and drug development industry seems to be taking. The competition just in nano tech is fierce and the big money is in USA. The dots do appear to be aligning slowly, mostly in university labs it would appear at the moment. A well established drug company is where the next big leap has to come from.
Eck often seems to be the subject of mysterious big late reported trades ending the day with various different closing prices. The consensus seems to be 41.80p price will out in the end!
Highly recommend looking at the EpiVax website. Whether this is report is a commission or endorsement it is the best piece of news I have read about N4p. It almost worries me that there has been so little reaction to it. Why anyone would sell now is also quite weird. Any way new hope for holders and cancer sufferers. They must succeed.
At last some meaningful news. An email of a report that concludes that Nuvec could help the treatment of ‘refactory cancer’, a cancer that is resistant to either the beginning of conventional treatment or becomes resistant to repeated conventional treatments. The report should help progress towards clinical trials
As happens with many companies listed on AIM, they lose 90 percent or more of their value from listing , especially when they have no revenue and continually rely on placings to stay afloat. The advantage of being listed was shown when N4p was able to raise funds to buy Nanogenics recently, who not being listed could not raise the money they needed to stay afloat. This provides opportunities for listed companies to add T bargain prices. Don’t k ow why Nigel feels the need to RNS every single patent news. It’s hardly price sensitive news and they have a website and now an investor hub. Price sensitive news is when they start making money or get a partner.
And now tipped by Gervais at Premier Miton, long term holders, if somewhat reduced. Perhaps they will load up again!
Seems to have caught Paul Scott’s attention on Stockopedia at long last. Having appeared to be rather disinterested in recent years and the data they have is well of date, the positive update caught his eye fleetingly. What ever you think of his views there can be no doubt they carry some influence on the private investor and of course he is a very competent numbers man
Disappointing reaction.more or less expected in this climate . Good results -10 percent , mediocre results -25 percent, bad results -50 percent or ground zero. Paul Hill thinks fair value £9 with the success of Magnetica and Adaptix, which is looking more probable than not . Potential sale to fund investment ? The market is such a dick at the moment. Opportunity though
Going to need another placing for all the RNS releases!
Good for IG to hold as long as they did. Must be all of a week! Patent granted in India ‘shows the strength of their intellectual property.’ Look forward to the day we can say thank god they did that.
Monument the company that was spun out of Cog could be worth half their market cap. It’s quite ridiculous. They still have a 25 percent interest in that. Doesn’t mean it’s the bottom though. This is Aim , it’s mad!
Don’t know if people have seen the Eckoh Call Guard demo but highly recommend if invested. They claim to have more Fortune Five Hundred clients than their combined competitors. This is set to grow for very good reasons as explained in the Stella Asset Management interview with Paul Hill on Vox markets.
Typical reaction from a nervous market. There have been some similar reaction to strong results from other Aim companies this month. 18.8 revenue almost doubled to £36 million full year. Cash was up about £4 million after specially div of over £10 million. This was a strong in line performance. Should be more news about the permanent introduction of a dividend in March statement. Appointment of joint broker/financial advisor is interesting . Does that mean they don’t have much confidence in Singer? I’m sure there was mention of a partnership last year. Again will need to see March statement on that too. Griffith trimmed his holding from 29 percent to 23 percent, which is understandable. Stanley came aboard for 5 percent when the shares were high 60p’s. All looks pretty fine to me. Mills said if we get lucky should get bought out. I wondered if financial advisor has been installed for that eventuality. The world is not in a good place right now so the much talked about bull return looks to be on hold. Gl
Utterly pathetic response to great results. Well done Miles and team. Shows how screwed the market is right now. As usual the uk market is the most pathetic. Sadly I think we will eventually loose many of our best companies either to the USA where many operate a high percentage of their business or they just get bought out on the cheap by American investment companies
It maybe that the Syntec acquisition is finally paying its way. Brief mention in Stella Asset Management interview with Paul Hill on Vox Market last week. It could be that the Screwfix contract is an updated secure payment version, in which case it is a new contract theoretically. Not sure why it’s not worthy of an RNS. It seems the focus of the business is now firmly addressing the USA market which will be 90 percent of their business . Quite a seismic shift, and clearly a massive scale up. Stellar Asset say we should see a big step up from April. Look forward to it.
Feedback ‘how likely am I going to recommend N4p to another investor’ well Nigel once you realise the objective of a business is to make money and not just a 20 year loss making concept that keeps asking the market for more money, then I might just say this is more than just a very long trial going nowhere. Nowhereman please listen , seems obvious what your missing. All it is at the moment is university projects. One day Rodney……